Our unique approach uses complex assays and treatment algorithms to help your doctor prescribe the right high blood pressure drugs that will work for you. With Geneticure, you’ll discover the personalized physiology and genetics associated with your hypertension that show the function of your heart, kidneys and blood vessels. Our method goes beyond most DNA tests that only look at drug metabolizing enzymes — how much of a drug gets into your bloodstream. Drug metabolizing enzymes are primarily used to help guide the correct dosage, independent of whether or not it’s the right medication in the first place. With Geneticure, you’ll find out which medications might be most likely to work best for you, based not only on drug metabolism, but also enzymes, hormonal pathways, and drug receptors in your DNA.
Geneticure has 3 clinical trials on nearly 700 subjects demonstrating clinical and health economic utility, with 5 peer reviewed publications.
Chronic diseases like Hypertension are costly ($94B in the U.S annually), dangerous (as organ damage begins to occur immediately), and hard to treat.
The average 7-8mmHg drop in blood pressure when a medication is administered is only seen in 50% of the population while each of these medications have dramatic side effects. When these initial medications do not result in achieving blood pressure targets, the current standard of care recommends adding additional medication. As medications are added and dosages titrated, many visits are required & patients are often taking unnecessary medications that have long-term side effects. Trial-and-error of layering medications is not desirable. Side effects aren’t the only disadvantage to the layering of medication. For each medication added to a patient’s regimen, there is a 70% increase in non-compliance. These factors lead to 50% control rates for the leading preventable cause of death in the world.
Geneticure’s tests examine a series of genetic variants that determine which of the treatment options will work best for each unique patient, unique to each disease. Our patented tests go well beyond others in the pharmacogenomics field focusing on drug metabolism, which is meaningless for complex diseases driven by the genetics of integrative physiology. A simple cheek swab is sent to our CLIA-certified reference laboratory for genotyping. 3 Geneticure clinical trials and 100s of independent, peer-reviewed research have contributed to the selection and weighting of the variants most important in blood pressure treatment response. Our proprietary algorithm analyzes these results and provides a summary of ranked treatment recommendations allowing providers to take in the necessary multiple variables of a patient’s healthcare and select the prescription that is most likely to work right away. The Geneticure for hypertension solution has demonstrated the potential for meaningful improvements in outcomes (36% lower blood pressure vs. standard of care) and significant reductions spending (47% less expensive). Geneticure has additional chronic disease solutions in development with Mayo Clinic and Medtronic.
As patients continue to demand convenient and cost-effective solutions, we align those needs with health systems and payers. Geneticure can be seamlessly integrated into provider practice and employer group programs. Off-the-shelf kits are ready to use or efficiently delivered by mail. Provided with the kits are instructions on how to use and how to conveniently activate the kit using a secure patient and provider portal. Reports are delivered electronically with the opportunity of integration into an EMR system.
Our published evidence has shown payers receive a 16X return on investment from our $249 test, within 3 years. This is equivalent to $1,331 in savings per patient per year and 47% less expensive than standard of care, as published in the Journal of Medical Economics.
Patients and employers who are increasingly on the hook for healthcare spending will benefit from the same cost reductions in addition to fewer days of missed work for visits titrating and stacking ineffective medications.
Providers will benefit from new open office visits, freeing time for higher quality care and alleviating physician burnout. Our tests provide the guidance provider organizations need to achieve chronic disease management goals.
Chronic diseases compete for patient attention, urgency and prescription adherence. Patients and loved-ones are attracted to our value proposition of fewer trips to their primary care provider’s office and lowering their deadly blood pressure quicker with fewer medications. Our value proposition also includes improving overall prescription adherence by optimizing for only effective medications based on the patient’s unique genetics, thereby eliminating the current practice of layering medications. This allows for additional attention to competing diseases.
Geneticure has demonstrated that blood pressure in patients who used hypertension medications recommended by Geneticure was approximately 36 percent lower than in patients who were prescribed HTN medication that did not align with the Geneticure recommendation. This is equivalent to a 40% risk reduction in deadly events like heart attack and stroke. This groundbreaking research was published in the February 2019 issue of the Journal of Clinical Medicine.
We have completed 3 clinical trials totaling 684 subjects leading to 5 peer-reviewed publications and 13 presentations at scientific conferences. Our studies have shown a control rate of 97% within 6 months, with fewer medications and 43% less adverse events vs. the standard of care.
COVID-19 use cases:
Like in hypertension treatment, we have identified genetic influences within the renin-angiotensin-aldosterone system (RAAS) that we believe will be beneficial in predicting the severity of, and guiding treatment for, COVID19 patients.
COVID-19, like other coronaviruses, bind to and utilize, angiotensin-converting enzyme 2 (ACE2) as a host receptor in order to infect cells resulting in respiratory illness in humans. This is the lock-and-key allowing entry into the cells.
As we all have learned, some can carry and transmit the virus without any symptoms, some with mild symptoms, and some with severe enough complications resulting in death.
Hypertension can cause changes in the RAAS (as an important counter-regulatory pathway to balance increases in blood pressure) and common blood pressure medications have shown to modulate ACE2 levels in small trials.
Several other clinical comorbidities and demographic variables including diabetes, age, and sex have been shown to cause changes in the RAAS in animal models: these are all associated with differences in COVID-19 presentation.
Using the data that are available from these patients with varying levels of severity, it is clear that differences in endogenous ACE2 levels may alter the risk of disease transmission along with the degree of severity of disease progression.
Not all hypertensives, diabetics, or men develop COVID-19, and many without these factors ultimately develop COVID-19 at varying degrees of severity, suggesting genetics may be one of many factors that is important.
Interestingly, there are important potential differences in the importance of ACE2 pre-vs. post-infection. With high ACE2 levels likely being protective for the heart and lungs post-infection. Given this complex relationship: further study is certainly warranted.
With our cheek-swab test, we can identify patients who likely have low vs. high ACE2 levels, based on genetic variants important in the RAAS, to triage their risk for disease progression. We are beginning clinical research trials on this.
We can also utilize this genetic information to suggest common medication adjustments that can be utilized to reduce ACE2 concentrations, hopefully improving outcomes and saving lives.
Health Systems, Employers, Pharmacy
Differentiators vs EHR Functionality:
Clinically there has been no other option, so it's natural to think the current way of doing things
is 'fine.' If you invert, and Geneticure and standard of care were both available, there is much
There most certainly is a problem with how we prescribe medications, and population-wide
results from the standard of care are pretty dismal[1, 2]. There have been minimal meaningful
advances in HTN care in recent years, and this has led to complacency with the standard of
care. Despite the perception that current time to control the disease is good, control rates are
abysmal, and that is extremely costly ($94B annually in the U.S.).
End organ damage begins to occur immediately with high BP. 40% of patients on meds and
taking medications as prescribed by their clinician (confirmed with urine testing and mass
spectrometry) are not under control, they are on the wrong therapy. Additionally, even if
patients achieve their blood pressure goal in 6-8mo, patients are very often taking unnecessary
medications for life that have long term side effects or some that may cause blood pressure to
There is a very under-appreciated bell-curve (variable) response to BP therapy. 40-50% of
patients respond to each medication, even when adherence is confirmed. Meaning, this is not
due to lack of compliance. The average reduction in BP for any medication is 7-8mmHg over the placebo effect, and each medication class has dramatic side effects  [6, 7].
Because of this, layering of medications that may or may not work will not be a best clinical
practice in the future: for each medication added to a patient's regimen, there is a 70% increase
in non-compliance. Not to mention the millions of patients that don't have the financial
means or discipline for 6-8 months of trial and error.
All of these factors lead to 50% control rates for the leading preventable cause of death in the
world, and I think most would argue that's not good enough. Given our approach has and will
continue to demonstrate clinical and economic superiority, clinicians will eventually be putting
patients in harm's way by not adopting.
We recognize this will take time and capital, but we will get there with our great partners like
Mayo Clinic, Omron, and Medtronic. Payers stand to save billions (as we are 47% less expensive
than standard of care, demonstrated by peer-reviewed evidence).
Patients and employers who are increasingly on the hook for healthcare spending will benefit
from the same cost reductions. Additional benefits include less missed work for trial and error
and less "pill fatigue." Therapy non-adherence will diminish by eliminating the stacking of
medications, which also impacts other diseases. None of these factors are included in our 47%
cost savings evidence and will be accretive to the value.
Providers will benefit from millions of open office visits, freeing time for higher quality (and
more profitable) visits. There will be a meaningful contribution to alleviating physician burnout
as we continue to apply the same approach to additional titration/switching visits across other
similar chronic diseases. For this reason, we anticipate a future where our diagnostic is required
before prescribing medications.
Summarizing key points:
• Each conventional BP medication has a bell-curve response with some patients showing
a drop, some demonstrating no change, and approximately 20% showing an increase in
BP. This variability is well-studied and true of each of the standard BP medication
• Each BP medication has an average response rate of 50% in the population.
• Even when patients are adherent and taking their medications, as prescribed, 40% of
these individuals still do not have BP under control.
• There is a problem with layering medications
• Each medication has a pronounced side-effect profile. These are not harmless
• For each pill that we add to a patient's regimen, medication non-adherence increases by
70%. Non-adherence is a big problem in hypertension.
• We have the only PGen HTN panel that has actual data behind it (in peer-reviewed
• We have demonstrated that patients who match our drug recommendation #1 show
36% lower BP from diagnosis to controlling BP.
• Even with patients on monotherapy: if they match our recommendation, they are 50%
more likely to meet the new more stringent blood pressure guidelines.
• In a small pilot RCT against the standard of care (JNC-8, AHA, ACC guidelines), we
demonstrated half of the serious adverse events, when compared to the standard of care.
1. Egan, B.M., Y. Zhao, and R.N. Axon, US trends in prevalence, awareness, treatment, and control of
hypertension, 1988-2008. JAMA, 2010.303(20): p. 2043-50.
2. Carey, R.M. and P.K. Whelton, The 2017 american college of cardiology/american heart associaBon
hypertension guidelines: A resource for pracBcing clinicians. Annals of Internal Medicine, 2018.168(5): p. 359-
3. Gu, Q., et al., Trends in anBhypertensive medicaBon use and blood pressure control among United
States adults with hypertension: the NaBonal Health And NutriBon ExaminaBon Survey, 2001 to
2010. Circula+on, 2012.126(17): p. 2105-14.
4. Turnbull, F., et al., Effects of different blood pressure-lowering regimens on major cardiovascular
events in individuals with and without diabetes mellitus: results of prospecBvely designed overviews of
randomized trials. Arch Intern Med, 2005. 165(12): p. 1410-9.
5. Materson, B.J., et al., Single-drug therapy for hypertension in men. A comparison of six
anBhypertensive agents with placebo. The Department of Veterans Affairs CooperaBve Study Group on
AnBhypertensive Agents. N Engl J Med, 1993. 328(13): p. 914-21.
6. Gong, Y., et al., Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-
Blockers in Hypertensive African Americans. Hypertension, 2016.67(3): p. 556-63.
7. Chapman, A.B., et al., Predictors of anBhypertensive response to a standard dose of
hydrochlorothiazide for essenBal hypertension. Kidney Int, 2002.61(3): p. 1047-55.
8. Gupta, P., et al., Risk Factors for Nonadherence to AnBhypertensive Treatment. Hypertension,
2017.69(6): p. 1113-1120.
Differentiators vs Competitors:
Geneticure’s tests examine a series of genetic variants that determine which of the treatment options will work best for each unique patient, unique to each disease. Our patented tests go well beyond others in the pharmacogenomics field focusing on drug metabolism, which is meaningless for complex diseases which are driven by the genetics of integrative physiology.
As important, we lead with evidence-first. We've conducted three clinical trials and have six peer reviewed publications. Our tests are also patented.
AVIA Connect is where innovative health systems and hospitals go to find the right digital health solutions. It’s built to efficiently search vendors and guide informed decisions, with tools like product comparisons, match scores, report generators, peer reviews, and market insights.
AVIA Connect is brought to you by AVIA, a trusted company and community of experts who guide health systems on their digital transformation journey.
Stay up to date
Keep up with the latest products and trends in digital health.